EUVIMEDEUVIMED entdecken
Crossref

Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1

Kaito Ueda iD, Tatsuki Sato, Jumpei Sasaki, Kazuki Hashiba, Tomonari Mizuno, Hiroshi Yamada, Masayuki Sugimoto

Nucleic Acid Therapeutics · 2026

DOI: 10.1177/21593337261469503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2026. Verfasst von Kaito Ueda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nucleic Acid Medicine Business Division, Drug Delivery Research and Development Department, Corporate Technology Sector, Nitto Denko Corporation, Iba…. Hauptthemen laut MEDLINE: RNA, Small Interfering, Nanoparticles, Adaptor Proteins, Signal Transducing, Lipids. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Nitto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticles (LNPs) are clinically validated carriers for the delivery of small interfering RNA (siRNA). Their efficient tissue accessibility and cellular uptake complement conjugated siRNA approaches. While chemical modifications are critical for stabilizing siRNAs and enhancing their potency (particularly in conjugated formats), their contribution in LNP delivery is not fully understood. Here, we systematically evaluated advanced sequence-modification patterns in siRNAs targeting YAP1 and WWTR1 to define their impact on LNP-siRNAs. We found that siRNAs fully incorporating 2′- O -methyl (2′-OMe), 2′-fluoro nucleotides achieved superior knockdown efficacy in vivo compared with partially modified LNP-siRNAs typically used in clinical drugs. Further increasing the proportion of 2′-OMe to 86% did not impair RNA interference activity, and DNA substitutions provide additional opportunities for structural optimization to collectively enhance knockdown efficacy in mouse liver. In contrast, 5′-( E )-vinylphosphonate modification of the guide strand provides no benefit to knockdown efficacy in vitro or in vivo , likely owing to differences in endosomal trafficking between LNP and conjugated siRNAs. These findings provide a framework for chemical optimization of LNP-based siRNAs. The generation of siRNAs with greater efficacy and longer durability facilitates lower doses with less frequent administration, which mitigates LNP-associated toxicity and improves the therapeutic potential of LNP delivery systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingNanoparticlesAdaptor Proteins, Signal TransducingLipidsPhosphoproteinsIntracellular Signaling Peptides and ProteinsAnimalsHumansYAP-Signaling ProteinsMiceRNA InterferenceTranscription FactorsLiposomes

Stichwörter der Autor:innen

LNPRNAichemical modificationssiRNA

Substanzen

RNA, Small InterferingYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingYAP1 protein, humanLipidsPhosphoproteinsIntracellular Signaling Peptides and ProteinsTranscription FactorsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Nucleic Acid Medicine Business Division, Drug Delivery Research and Development Department, Corporate Technology Sector, Nitto Denko Corporation, Ibaraki, Osaka, Japan.
  • Faculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Sakyo-ku, Kyoto, Japan.

ORCID-Profile: Kaito Ueda

Förderung

  • Nitto

Zitieren

APA

Ueda, K., Sato, T., Sasaki, J., Hashiba, K., Mizuno, T., Yamada, H., & Sugimoto, M. (2026). Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337261469503

Vancouver

Ueda K, Sato T, Sasaki J, Hashiba K, Mizuno T, Yamada H, et al. Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1. Nucleic Acid Therapeutics. 2026. doi:10.1177/21593337261469503

BibTeX
@article{Ueda2026,
  author = {Ueda, Kaito and Sato, Tatsuki and Sasaki, Jumpei and Hashiba, Kazuki and Mizuno, Tomonari and Yamada, Hiroshi and Sugimoto, Masayuki},
  title = {Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1},
  journal = {Nucleic Acid Therapeutics},
  year = {2026},
  doi = {10.1177/21593337261469503}
}
Kostenlos starten →